Shareholder Investigation of Akorn, Inc. (AKRX)

Robbins LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Akorn, Inc. (NasdaqGS: AKRX) breached their fiduciary duties to shareholders. In a landmark ruling last week, a Delaware Court determined that Fresenius SE could walk away from its $4.3 billion deal to buy pharmaceutical manufacturer Akorn. Soon after the parties signed the deal documents, Akorn’s financials slumped dramatically. When Fresenius found that Akorn had breached U.S. Food and Drug Administration data integrity requirements, the company terminated the deal due to Akorn’s “failure to fulfill several closing conditions.” The court agreed that Fresenius validly ended the merger agreement because Akorn’s regulatory compliance representations were false. On this news, Akorn’s shares plummeted over 58% to $5.36, their lowest level in seven years.

Akorn Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.

Send us a message for more information.

Skip to content